Welcome to our dedicated page for Optimizerx news (Ticker: OPRX), a resource for investors and traders seeking the latest updates and insights on Optimizerx stock.
OptimizeRx Corporation reports developments in healthcare technology for life sciences marketing, with updates centered on tools that connect pharmaceutical brands with healthcare professionals and patients. The company’s platform uses EHR-based access, omnichannel activation, the Dynamic Audience Activation Platform, and Micro-Neighborhood audiences to support HCP and direct-to-consumer engagement.
Recurring OptimizeRx news includes product and network launches, programmatic access to EHR advertising, privacy-safe identity resolution collaborations, quarterly and annual results, debt and share-repurchase actions, and board or leadership changes. Coverage also reflects the company’s focus on privacy-compliant audience targeting and campaign measurement across healthcare marketing channels.
OptimizeRx Corp. (Nasdaq: OPRX) reported a remarkable 46% revenue increase for Q1 2020, reaching a record $7.6 million. Gross profit also rose by 20% to $4.3 million, though gross margin declined to 57.3% due to a favorable product mix last year. Operating expenses surged to $6.6 million, leading to a net loss of $2.2 million ($0.15 per share). The company is transitioning to a recurring revenue model with significant enterprise engagements. Cash reserves stood at $15.2 million. Management remains optimistic about growth amid increasing demand for digital health solutions.